KRON – kronos bio, inc. (US:NASDAQ)

News

Kronos Bio Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 [Yahoo! Finance]
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
Kronos Bio, Inc. (NASDAQ: KRON) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.
Kronos Bio, Inc. (NASDAQ: KRON) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $6.00.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com